SEC Filing Update: #KYMR Kymera Therapeutics, Inc. : $117.74

Sector: Healthcare | YTD: 🔼+ 61.89% The SEC disclosed Today (08-SEP-2026) that PRICE T ROWE ASSOCIATES INC MD has INCREASED #KYMR Shares by 24.76% 🟢 * Previous Holdings: 7.11M Shares * Current Holdings: 8.87M Shares * Increase+1.76M * Increased(%)+24.76% * Ownership: 10.7% * Estimated Investment Value: $211.23M https://www.thinksabio.com/reports/isr/KYMR The quarterly average prices of #KYMR: Q3 2025: $45.11 Q4 2025: $67.32 Q1 2026: $79.24 Q2 2026: $85.92 📈 Stay ahead of institutional buy/sell moves — Sign up free at ThinkSabio: Sign Up Free → 🐦 See this update on X: https://x.com/Thinksabio/status/2097328312913699079 T. Rowe Associates Inc. increased its position in Kymriah by 1,761,243 shares, from 7,112,345 to 8,873,588 shares, representing 10.7% ownership.